Under construction – not a live service
Sign in
Not yet taking people in ChinaPhase 3

LBL-024 With Chemotherapy as First Treatment for Advanced Extrapulmonary Neuroendocrine Carcinoma

Tests LBL-024 added to chemotherapy in adults with advanced extrapulmonary neuroendocrine carcinoma.

Plain-language title generated from the registry record
Registry title: A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC

Key facts

Where
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shengyang, Taiyuan, Tianjin, Wenzhou, Xi’an, Xiamen, Xinxiang, Xuzhou, and Zhengzhou, ChinaSee the 36 sites
Phase
Phase 3

Where in China

  • Anyang Tumor HospitalAnyang, ChinaNo longer taking part
  • Beijing Cancer HospitalBeijing, ChinaNo longer taking part
  • Beijing GoBroad HospitalBeijing, ChinaNo longer taking part
  • The First Affiliated Hospital of Bengbu Medical UniversityBengbu, ChinaNo longer taking part
  • The First Hospital of Jilin UniversityChangchun, ChinaNo longer taking part
  • Hunan Cancer HospitalChangsha, ChinaNo longer taking part
  • Sichuan Provincial People's HospitalChengdu, ChinaNo longer taking part
  • Chongqing University Cancer HospitalChongqing, ChinaNo longer taking part
  • Fujian Cancer HospitalFuzhou, ChinaNo longer taking part
  • Fujian Medical University Union HospitalFuzhou, ChinaNo longer taking part
  • The First Affiliated Hospital of Fujian Medical UniversityFuzhou, ChinaNo longer taking part
  • Sun Yat-sen University Cancer CenterGuangzhou, ChinaNo longer taking part
  • The First Affiliated Hospital of Jinan UniversityGuangzhou, ChinaNo longer taking part
  • The First Affiliated Hospital, Sun Yat-sen UniversityGuangzhou, ChinaNo longer taking part
  • Zhejiang Cancer HospitalHangzhou, ChinaNo longer taking part
  • Harbin Medical University Cancer HospitalHarbin, ChinaNo longer taking part
  • Shandong Cancer HospitalJinan, ChinaNo longer taking part
  • Yunnan Cancer HospitalKunming, ChinaNo longer taking part
  • Gansu Cancer HospitalLanzhou, ChinaNo longer taking part
  • The First Affiliated Hospital of Henan University of Science &TechnologyLuoyang, ChinaNo longer taking part
  • The Second Affiliated Hospital of Nanchang UniversityNanchang, ChinaNo longer taking part
  • The Affiliated Hospital of Nanjing university Medical SchoolNanjing, ChinaNo longer taking part
  • Guangxi Medical University Cancer HospitalNanning, ChinaNo longer taking part
  • Fudan University Shanghai Cancer CenterShanghai, ChinaNo longer taking part
  • Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaNo longer taking part
  • Liaoning Cancer Hospital and InstituteShengyang, ChinaNo longer taking part
  • First Hospital of Shanxi Medical UniversityTaiyuan, ChinaNo longer taking part
  • Shanxi Provincial Cancer HospitalTaiyuan, ChinaNo longer taking part
  • Tianjin Medical University Cancer Institute & HospitalTianjin, ChinaNo longer taking part
  • The First Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaNo longer taking part
  • The First Affiliated Hospital of Xi'an Jiaotong UniversityXi’an, ChinaNo longer taking part
  • The First Affiliated hospital of Xiamen UniversityXiamen, ChinaNo longer taking part
  • The First Affiliated Hospital of Henan Medical UniversityXinxiang, ChinaNo longer taking part
  • The affiliated hospital of xuzhou medical universityXuzhou, ChinaNo longer taking part
  • Henan Cancer HospitalZhengzhou, ChinaNo longer taking part
  • The First Affiliated Hospital of Zhengzhou UniversityZhengzhou, ChinaNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Nanjing Leads Biolabs Co.,Ltd
Trial code
NCT07720193
Record updated
19 October 2026
Original description
This trial is a randomized, double-blind, placebo-controlled multicenter phase III clinical study aiming to evaluate the efficacy and safety of LBL-024 compared with placebo in combination with etoposide and cisplatin or carboplatin (EP or EC) for the first-line treatment of advanced EP-NEC patients.Read full original descriptionShow less

A Randomized, Double-blind, Placebo-controlled, Phase III Trial of LBL-024 Combined With Platinum-based Chemotherapy as First-line Treatment of Patients With Advanced Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)

This trial is a randomized, double-blind, placebo-controlled multicenter phase III clinical study aiming to evaluate the efficacy and safety of LBL-024 compared with placebo in combination with etoposide and cisplatin or carboplatin (EP or EC) for the first-line treatment of advanced EP-NEC patients.

Inclusion: Agrees to follow the investigational treatment protocol, visit schedule and laboratory test, comply with other requirements of the protocol, voluntarily enroll, and sign a written informed consent; Age ≥ 18 years (inclusive) at the time of signing informed consent; The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0~1; expected survival time of at least 12 weeks; According to RECIST 1.1, participants were required to have at least one measurable lesion; Male of childbearing potential and Females of childbearing age are willing to take highly effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug.

Exclusion: Major surgery (other than aspiration biopsy) within 28 days prior to the first dose of study drug or significant trauma,or required to undergo scheduled surgery during the trial; Use of immunomodulatory drugs within 14 days before the first use of study drug,Including but not limited to thymopeptide, interleukins, interferon, etc; Patients with active infection requiring intravenous anti-infective therapy within 2 weeks prior to the first dose of study drug; serious cardiac and cerebrovascular disorder; History of immunodeficiency including HIV antibody test positive; patients with active hepatitis B or C; The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study; Diagnosed with Mixed neuroendocrine-non endocrine neoplasm (MiNENs); Women during pregnancy or lactation.

ClinicalTrials.gov NCT07720193